William E. Duke - 23 Aug 2023 Form 4 Insider Report for Apexigen, Inc.

Role
Chief Financial Officer
Signature
/s/ Francis Sarena, by power of attorney
Issuer symbol
N/A
Transactions as of
23 Aug 2023
Net transactions value
-$10,173
Form type
4
Filing time
25 Aug 2023, 19:42:49 UTC
Previous filing
23 Jun 2023
Next filing
05 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APGN Common Stock Tax liability $10,173 -26,416 -17% $0.3851 128,001 23 Aug 2023 Direct F1
transaction APGN Common Stock Disposed to Issuer -128,001 -100% 0 23 Aug 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APGN Employee Stock Option (right to buy) Disposed to Issuer -269,848 -100% 0 23 Aug 2023 Common Stock 269,848 $2.46 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

William E. Duke is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units.
F2 Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the "Merger Agreement"), by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), each share of Issuer common stock was exchanged for 0.1725 shares of Pyxis common stock and rounded down to the nearest whole share.
F3 One-fourth of the shares vested on June 6, 2023 and 1/48th of the shares vest monthly thereafter. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 46,547 shares of Pyxis common stock at an exercise price of $14.27 per share.